Cambridge, MA
Aviceda Therapeutics is a late-stage, pre-clinical stage biotech company focused on the next generation of immuno-modulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly.
avicedarx.comThese are collections Aviceda Therapeutics is a part of. Click on the collection name to view similar companies.
Series C
$207,500,000
Series Unknown
$15,610,000
Series Unknown
$49,450,983
Series Unknown
$4,250,000
0 out of 5 stars
Based on 0 reviews
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Aviceda Therapeutics.